IS THERE ENOUGH EVIDENCE TO USE BISPHOSPHONATES IN HIV-INFECTED PATIENTS? A SYSTEMATIC REVIEW AND META-ANALYSIS.

  1. Inicio
  2. »
  3. Sin categoría
  4. »
  5. IS THERE ENOUGH EVIDENCE TO USE BISPHOSPHONATES IN HIV-INFECTED PATIENTS?...

In conclusion, administration of oral and intravenous bisphosphonates was associated with increased bone mineral density at the lumbar spine and total hip over two years in HIV-positive patients. However, none of the included trials were long enough to detect the impact of bisphosphonates on a clinically important outcome such as fracture risk.

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro
Faes Farma
Meiji Pharma